CG Oncology, Inc. ( (CGON) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CG Oncology, Inc. shares are sliding as investors react to concerns about future dilution and rising competition in bladder cancer treatments. Market sentiment has turned cautious after the recent surge to a fresh 52-week high.
The stock is under pressure following the company’s move to boost its at-the-market stock offering by $300 million, lifting potential sales to $550 million. Traders are also digesting new clinical data from Johnson & Johnson in non-muscle invasive bladder cancer, which underscores a tougher path ahead for CG Oncology’s lead drug, cretostimogene.
More about CG Oncology, Inc.
YTD Price Performance: 65.32%
Average Trading Volume: 1,247,567
Technical Sentiment Signal: Buy
Current Market Cap: $5.8B
For further insights into CGON stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.